



Corban & Blair
A team of designers, problem solvers and makers who create bespoke presentation and marketing products in Sydney

QUOTE REQUEST

- ABOUT US ▾
- NEWS
- OUR ANALYSIS
- TECHNOLOGY
- MEMBER FOCUS ▾
- OUR SERVICES ▾
- SUPPORT US ▾

Search

NOXOPHARM INVESTIGATES COVID-19 TREATMENT

Home / News / Noxopharm investigates Covid-19 treatment



Drug developer Noxopharm is following up on indications that an experimental anti-cancer

drug may be effective against the Covid-19 coronavirus.

Melbourne’s Hudson Institute of Medical Research has identified anti-inflammatory properties of the experimental drug idronoxil, the active ingredient in the company’s anti-cancer drug candidate Veyonda.

Pre-clinical models indicate the drug has the ability to treat patients with early-stage organ failure, reducing the need for intensive care.

Noxopharm said in a statement that idronoxil inhibited an abnormally excessive inflammatory response known as cytokine storm believed to be responsible for the death of some virus sufferers.

The company now proposes to evaluate the drug use in patients at risk of developing acute respiratory distress syndrome and multi-organ failure.

Noxopharm has applied for provisional patent protection for its development and will seek partners to conduct further research.


This will also investigate whether the new approach to using the drug can be a treatment for septic shock generally.

Picture: Noxopharm

Subscribe to our free @AuManufacturing newsletter [here](#).

By Peter Roberts April 2, 2020

Share this post



Author: Peter Roberts

PREVIOUS

◀ **R.M. Williams closes factory, stands down 709 workers**

NEXT

Calix gets green light for cement industry CO2 capture ▶

Related Posts

CSIRO begins testing Covid-19 vaccines as part of global effort
April 2, 2020

“Dodgy” PPE masks from China worth \$1.2 million seized at border: report
April 2, 2020

Calix gets green light for cement industry CO2 capture
April 2, 2020

Drug companies should drop their patents and collaborate to fight coronavirus
April 2, 2020

Launch of 2020 media kit, an introduction, and a special offer from @AuManufacturing
April 2, 2020

R.M. Williams closes factory, stands down 709 workers
April 1, 2020

Leave a Reply

Your email address will not be published. Required fields are marked *

Comment

Name*

Email*

Website

Save my name, email, and website in this browser for the next time I comment.

I'm not a robot reCAPTCHA
Privacy - Terms

Post comment

This site uses Akismet to reduce spam. [Learn how your comment data is processed.](#)

Recent Posts



CSIRO begins testing Covid-19 vaccines as part of global effort

April 2, 2020



Drug companies should drop their patents and collaborate to fight coronavirus

April 2, 2020



“Dodgy” PPE masks from China worth \$1.2 million seized at border: report

April 2, 2020



Launch of 2020 media kit, an introduction, and a special offer from @AuManufacturing

April 2, 2020



Calix gets green light for cement industry CO2 capture

April 2, 2020



Noxopharm investigates Covid-19 treatment

April 2, 2020

@AuManufacturing

@AuManufacturing is news and analysis for the Australian manufacturing sector. Follow us on Twitter & LinkedIn.

Search

Type and hit enter ...



@AuManufacturing on Twitter



AustralianManufacturingForum

Follow

AustralianManufacturingForum Retweeted

1h

Join Australia's manufacturing community! Launch of 2020 media kit, an introduction, and a special offer from @AuManufacturing #manufacturing <https://www.aumanufacturing.com.au/launch-of-2020-media-kit-...>

1 [Twitter](#)

1h

.@noxopharm is following up on indications an experimental anti-cancer drug may be effective against the Covid-19 #coronavirus.

<https://www.aumanufacturing.com.au/noxopharm-investigates-co...>

[#COVID19au](#) [#covid19](#) [#medtech](#) [#research](#)

[Twitter](#)

Topics

3D printing (62)

Analysis and
Commentary
(210)Automation and
robotics
(26)

Big Issues (183)

Company (554)

Digitalisation
(28)

Events (37)

Features (681)

Government and
Policy
(250)Grants and
funding
(205)

IoT (82)

Management
(18)

News (33)

Materials (86)

Meet a Member
(12)

Members (72)

News (1458)

News Briefs
(252)Process
improvement
(49)Procurement
(106)Product
development
(98)

R&D (165)

Software (10)

Supply chain
(52)Technology
(154)Training and skills
(21)Trends and
market research
(32)**Signup for Email News**

Name *

First

Last

Email *

Postcode *

Submit